Dylan Demars
Psychiatric/Mental Health · Fort Myers, FLNPI 1619575818
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,975 of the $23,930 with a category attached, or 79.3%. AbbVie accounts for 84.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $13,409 and has fallen 70.6% since, to $3,949 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $96.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Supernus Pharmaceuticals, Inc.$469
- Neurocrine Biosciences, Inc.$432
- Alkermes, Inc.$340
- Otsuka America Pharmaceutical, Inc.$320
- Corium, LLC$230
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$18,97579%
- Travel & lodging$1030%
- Food & beverage$4,85120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $20,234 |
| Supernus Pharmaceuticals, Inc. | 19 | $469 |
| Neurocrine Biosciences, Inc. | 18 | $432 |
| Alkermes, Inc. | 16 | $340 |
| Otsuka America Pharmaceutical, Inc. | 16 | $320 |
| Corium, LLC | 13 | $230 |
| Neuronetics, Inc. | 2 | $223 |
| Johnson & Johnson | 10 | $219 |
| Vanda Pharmaceuticals Inc. | 10 | $188 |
| Axsome Therapeutics, Inc. | 10 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $164 |
| Sunovion Pharmaceuticals Inc. | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 7 | $133 |
| Tempus AI, Inc | 7 | $132 |
| Almatica Pharma LLC | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Lundbeck LLC | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| Tris Pharma Inc | 3 | $49 |
| Adlon Therapeutics L.p. | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$19,203
- NEUROSTAR TMS THERAPY SYSTEM$223
- QELBREE$201
How this compares
$23,930 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $152,079 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $50,436 |
| VraylarCariprazine Hcl | 30 | $47,717 |
| RexultiBrexpiprazole | 14 | $20,450 |
| TrintellixVortioxetine Hydrobromide | 11 | $11,257 |
| Chlorpromazine Hcl | 13 | $4,295 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 37 | $2,110 |
| Trazodone Hcl | 117 | $2,097 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,999 |
| Aripiprazole | 50 | $1,672 |
| Risperidone | 121 | $1,632 |
| Hydroxyzine Hcl | 95 | $1,592 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $1,499 |
| Oxcarbazepine | 43 | $1,240 |
| Bupropion XlBupropion Hcl | 50 | $889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $133 | $152,07917 claims |
| Alkermes, Inc.Lybalvi | $340 | $50,43633 claims |
| AbbVieVraylar | $20,234 | $47,71730 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $320 | $20,45014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $79 | $11,25711 claims |
| Almatica Pharma LLCSertraline Hcl | $90 | $33746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Fort Myers
- Jacqueline BannisterFort Myers$13K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.